View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
December 9, 2013

Dyax gets FDA orphan drug status for HAE drug DX-2930

US-based Dyax has received orphan drug designation from the US Food and Drug Administration (FDA) for its drug candidate DX-2930, a novel, fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE).

By admin-demo

US-based Dyax has received orphan drug designation from the US Food and Drug Administration (FDA) for its drug candidate DX-2930, a novel, fully human monoclonal antibody inhibitor of plasma kallikrein, for use in the treatment of hereditary angioedema (HAE).

DX-2930 is being developed as a long-acting, prophylactic agent that prevents HAE attacks and the company’s drug development plans include a dosage formulation that will permit infrequent self-administration by small volume, subcutaneous injection.

The drug candidate is currently being evaluated in a placebo-controlled, dose-escalation Phase I study in normal individuals and the results are expected to be released in the first quarter of 2014.

"There is still a significant unmet medical need within the HAE community, which we plan to address with DX-2930."

Dyax president and chief executive officer Gustav Christensen saidL "There is still a significant unmet medical need within the HAE community, which we plan to address with DX-2930.

"Orphan drug designation is an important element of our development strategy for DX-2930 as we work to further improve the health and quality of life for individuals suffering from this painful and often debilitating condition."

DX-2930 was discovered using the company’s proprietary phage display technology platform.

According to the company, uncontrolled plasma kallikrein activity leads to excessive generation of bradykinin, a vasodilator thought to be responsible for the localised swelling, inflammation and pain characteristically associated with HAE.

The preclinical studies suggest that DX-2930 will have a long half-life in humans, providing the potential for a long-acting and sustained therapeutic effect with less frequent dosing.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology